Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sadar, M. D.
Right arrow Articles by Beraldi, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadar, M. D.
Right arrow Articles by Beraldi, E.
Vol. 1, 629-637, June 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Characterization of a New in Vivo Hollow Fiber Model for the Study of Progression of Prostate Cancer to Androgen Independence1

Marianne D. Sadar2, Violetta A. Akopian and Eliana Beraldi

Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6 Canada

Research investigating the molecular events underlying progression of prostate cancer to androgen independence has been impeded by the lack of an appropriate in vivo model that yields "pure" populations of prostate cancer cells that are not contaminated with host cells. Here we characterize a new in vivo model that uses hollow fibers and allows for the retrieval of uncontaminated prostate cancer cells during various stages of endocrine progression to androgen independence in male immunocompromised mice. Prostate-specific antigen (PSA) gene expression, proliferation of cells, and histology were examined in these mice before and after castration. LNCaP cells seeded at a density of 1 x 107 cells/ml, or a total of approximately 4.8 x 106 cells/animal, provided measurable serum PSA levels that increased in intact (noncastrated) animals, decreased by 80% to a nadir after castration, and subsequently increased by 4 weeks after castration, indicating progression to androgen independence. In vivo proliferation of LNCaP cells inside the fibers continued in the presence of androgens and continued to increase, albeit at a slower rate, in the castrated animals. Histology of cells cultivated in hollow fibers demonstrated that initially the cells grew along the wall of the fiber and tended to stack up, forming layers and scaffold structures resembling a solid tumor. Fibers removed from castrated animals with elevated levels of serum PSA contained spheroids of cells that had detached from the fiber wall. The development of the LNCaP hollow fiber model described here provides a reproducible means of obtaining "pure" populations of LNCaP cells during different stages of progression to androgen independence for molecular analysis requiring RNA and protein extracts free of host cell contamination.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. N. Quayle, N. R. Mawji, J. Wang, and M. D. Sadar
Androgen receptor decoy molecules block the growth of prostate cancer
PNAS, January 23, 2007; 104(4): 1331 - 1336.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Suggitt and M. C. Bibby
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Clin. Cancer Res., February 1, 2005; 11(3): 971 - 981.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Suggitt, D. J. Swaine, G. R. Pettit, and M. C. Bibby
Characterization of the Hollow Fiber Assay for the Determination of Microtubule Disruption In vivo
Clin. Cancer Res., October 1, 2004; 10(19): 6677 - 6685.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
J. C.L. Schuh
Trials, Tribulations, and Trends in Tumor Modeling in Mice
Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66.
[Abstract] [PDF]


Home page
Cancer Res.Home page
Z. Chen, K. S. Koeneman, and D. R. Corey
Consequences of Telomerase Inhibition and Combination Treatments for the Proliferation of Cancer Cells
Cancer Res., September 15, 2003; 63(18): 5917 - 5925.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.